This is the 59th situation report for the multi-country outbreak of mpox, which provides details on the global epidemiological situation for mpox, including an update on the epidemiological situation with data on the global…
It’s time to load up on Halloween candy, and while you’re at, why not start a holiday wish list? Black Friday is just a handful of weeks away and each year it seems retailers start dropping prices…
SPOILER ALERT: This piece contains spoilers for the Season 5 finale episode of Only Murders in the Building.
Another Arconia murder mystery has come and gone, but another dead body was found on the premises, though it could be argued that…
My fellow 1980s children, our old pal Pac-Man is back. And how in the world is he 45 years old already? The new Halloween Google Doodle is here to challenge us with a spooky-themed version of the classic arcade game on our computers and other…
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]
SOURCE Nektar Therapeutics
Prince Andrew will soon simply be known as Andrew Mountbatten Windsor after the process to strip the disgraced brother of King Charles III of all of his royal titles began today, but his daughters will keep theirs.
The formal process to remove…
Individuals diagnosed with
Researchers at the University of Chicago have developed a comprehensive mathematical model that predicts diabetes complications up to 15 years in advance, offering clinicians a powerful new tool to understand how early treatment decisions shape…
…
Five alleged drug dealers are facing felony charges for their involvement in the death of Leandro De Niro-Rodriguez, the grandson of acting legend Robert De Niro.
A federal grand jury in New York indicted the quintet on Tuesday, each on a…